Market Size of Crohn's Disease Diagnostic and Therapeutic Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 3.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Crohn's Disease Diagnostics and Therapeutics Market Analysis
The Crohn's disease diagnostics and therapeutics market is estimated to register a CAGR of 3.1% during the forecast period.
With the rise in COVID-19, the prevalence of other related complications also increased. According to a report by the SECURE-IBD database in January 2022, adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with IBD. The novel severe acute respiratory syndrome-related coronavirus activated innate and adaptive immune responses upon entering the gastrointestinal tract. The study shows IBD patients' inflammatory reactions may cause intestinal damage. Also, a research article published in the Journal of Crohn and Colitis in March 2020 showed that IBD patients undertaking immune suppressors are associated with a greater risk of infections, even though there is no evidence to suggest that COVID-19 affects IBD patients more commonly than the general population. According to a review article in the World Journal of Gastroenterology in October 2020, it was comprehended that many COVID-19 patients were found to develop gastrointestinal complaints. Thus, there is an increasing demand for the Crohn's disease diagnostics and therapeutics market to manage further complications that could develop due to COVID-19.
The increasing occurrence of Crohn's disease is the primary driver predicted to boost the growth of the market. According to a report by the CDC published on World IBD Day in April 2021, the number of people affected by IBD is around 7 million worldwide. The report also stated that the rate of prevalence of the disease significantly increased during the last two decades. The prevalence of chronic health conditions such as cancer, arthritis, migraine, and other cardiovascular, respiratory, kidney, and liver diseases are higher in IBD patients than in non-IBD patients. In the older population (66 years and above), patients with IBD were more susceptible to hospitalization for hip fractures. Also, they were found to have 30-day readmissions, and more extended hospital stays. Studies on the treatment of IBD for the prevention of such instances are a great boost to the development of the market during the forecast period.
The increasing awareness of Crohn's disease, coupled with rising initiatives by regulatory bodies to develop novel treatment options, is expected to provide the market studied with high growth potential.
Crohn's Disease Diagnostics and Therapeutics Industry Segmentation
Crohn's disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from the mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors in genetically predisposed individuals.
The Crohn's disease diagnostics and therapeutics market is segmented by diagnostics (blood test, fecal test, colonoscopy, flexible sigmoidoscopy, computerized tomography, magnetic resonance imaging, capsule endoscopy, other diagnostic tests), treatment (medication (anti-inflammatory agents, immunosuppressants, analgesics and antipyretics, other medications), surgery), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in terms of value in USD million for the above segments.
| By Diagnostics | |
| Blood Test | |
| Fecal Test | |
| Colonoscopy | |
| Flexible Sigmoidoscopy | |
| Computerised Tomography | |
| Magnetic Resonance Imaging | |
| Other Diagnostic Tests |
| By Treatment | ||||||
| ||||||
| Surgery |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Crohn's Disease Diagnostic and Therapeutic Market Size Summary
The Crohn's disease diagnostics and therapeutics market is poised for steady growth, driven by the increasing prevalence of the disease and the rising demand for effective management solutions. The market is experiencing a surge in interest due to the complications arising from COVID-19, which have highlighted the need for advanced diagnostics and therapeutics to address inflammatory bowel disease (IBD) patients' unique challenges. The market is characterized by a strong focus on anti-inflammatory agents, particularly non-steroidal anti-inflammatory drugs (NSAIDs), which continue to dominate the therapeutics segment due to their superior efficacy. The landscape is further bolstered by significant investments, clinical trials, and the activities of key players, such as Rise Therapeutics LLC and Cerecord, which are actively developing novel treatment options.
North America holds a significant share of the market, attributed to the high prevalence of Crohn's disease and the region's adoption of innovative medicines. The urbanization and lifestyle changes in this region have contributed to the increasing incidence of the disease, prompting a surge in research and development efforts. The market's growth is supported by strategic partnerships and collaborations, such as those between LifeArc and the Crohn's and Colitis Foundation, which aim to advance prognostic and therapeutic developments. The competitive landscape features both international and local companies, with major players like Pfizer Inc., Janssen Biotech Inc., GeneTech, Celgene Corporation, and AbbVie Inc. actively participating in the market. The ongoing efforts to develop novel therapeutics and the supportive regulatory environment are expected to drive the market's expansion in both developed and developing nations.
Crohn's Disease Diagnostic and Therapeutic Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
-
1.2.2 Demand for Prompt Diagnosis
-
1.2.3 Affected Population Increasing with Time
-
-
1.3 Market Restraints
-
1.3.1 No Specific Treatment or Drug Available in the Market
-
1.3.2 Lack of Awareness Among People and Symptom Similarity with Other Gastrointestinal Diseases
-
1.3.3 Lack of Cost-effective Treatment
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Diagnostics
-
2.1.1 Blood Test
-
2.1.2 Fecal Test
-
2.1.3 Colonoscopy
-
2.1.4 Flexible Sigmoidoscopy
-
2.1.5 Computerised Tomography
-
2.1.6 Magnetic Resonance Imaging
-
2.1.7 Other Diagnostic Tests
-
-
2.2 By Treatment
-
2.2.1 Medication
-
2.2.1.1 Anti-inflammatory Agents
-
2.2.1.2 Immunosuppressants
-
2.2.1.3 Analgesics and Antipyretics
-
2.2.1.4 Other Medications
-
-
2.2.2 Surgery
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Crohn's Disease Diagnostic and Therapeutic Market Size FAQs
What is the current Crohn's Disease Diagnostic and Therapeutic Market size?
The Crohn's Disease Diagnostic and Therapeutic Market is projected to register a CAGR of 3.10% during the forecast period (2024-2029)
Who are the key players in Crohn's Disease Diagnostic and Therapeutic Market?
Abbvie Inc., Celgene Corporation, GeneTech, Janssen Biotech Inc. and Pfizer Inc are the major companies operating in the Crohn's Disease Diagnostic and Therapeutic Market.
